by
Valérie Gras-Champel, Aline Munier and Ziad A. Massy
![]() |
![]() |
| Dr
Valérie Gras-Champel Clinical Pharmacology University Hospital of Amiens Amiens, France |
Prof
Z.A. Massy Nephrology and Clinical Pharmacology Departments University Hospital of Amiens Amiens, France |
![]() |
An
85-year-old woman weighing 65kg, was admitted to the intensive care unit
of our hospital for vomiting, abdominal pain, discomfort, confusion and
dyspnea, which had lasted for 48 hours. She had a history of diarrhea several
days before her admission with favorable spontaneous evolution. At this
time she self-administered aspirin (3g/day) for a few days. She was currently
being treated with metformin (2 x 850 mg/day) and simvastatin (10 mg/day)
for type-2 diabetes and hypercholesterolemia respectively.
At admission, physical examination showed body temperature of 37°, and
normal blood pressure. Plasma electrolyte levels were considered normal:
sodium=145 mEq/L; potassium=5.1 mEq/L, chloride=102 mEq/L. Arterial blood
gas analysis showed: pH=7.1; pCO2 =14.4 mmHg; pO2=134.2 mmHg; HCO3-=4.4
mmol/L. Additional blood tests demonstrated: creatininemia=130 µmol/L;
glucose = 5 mmol/L; blood lactatemia=33 mmol/L; ketonemia= 0.3 mmol/L, ketonuria=1.10
mmol/24h; transaminases=120 UI/L; TP=90%. White blood cells=5200/mm3.
![]() |
Chemical
structure of two members of the biguanid family. |
REFERENCES
| 1. | Jones GC, Macklin JP, Alexander WD. Contraindications to the use of metformin. Br Med J 2003; 326: 4-5. Pubmed Link |
| 2. | Lalau JD, Race JM. Lactic Acidosis in Metformin-Treated Patients – Prognostic Value of Arterial Lactate Levels and Plasma Metformin Concentrations. Drug Saf 1999; 20 (4): 377-384. Pubmed Link |
| 3. | Chang C, Chen YC, Fang JT, Huang CC. Metformin-associated lactic acidosis: case reports and literature review. J Nephrol 2000; 15: 398-402. |
| 4. | Lalau JD, Race JM. Metformine and lactic acidosis in diabetic humans. Diabetes Obesity Metab, 2000; 2: 131-137. Pubmed Link |
| 5. | Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003; 163 (21): 2594-602. Pubmed Link |
| 6. | Trischitta V, Gullo D, Pezzino V, Vigneri R. Metformin Normalizes Insulin Binding to Moncytes from Obese Nondiabetic Subjects and Obes Type II Diabetic Patients. J Clin Endocrinol Metab 1983; 57 (4); 713-718. Pubmed Link |
| 7. | Menzies DG, Campbell IW, McBain A, Brown IR. Metformin efficacy and tolerance in obese non-insulin dependent diabetics: a comparison of two dosage schedules. Curr Med Res Opin 1989; 11 (5); 273-278. Pubmed Link |
| 8. | Lalau JD, Vermersch A, Hary L, Andrejak M, Isnard F, Quichaud J. Type 2 diabetes in elderly: an assessment of metformin. Int J Clin Pharmacol Ther Toxicol 1990; 28: 329-332. Pubmed Link |
| 9. | UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865. Pubmed Link |
Acknowledgements:
The author is indebted to Prof Michel Andrejak, and Dr Henri Masson for
revising the manuscript and making useful suggestions, as well as Prof Jean-Daniel
Lalau for his useful help regarding the bibliography.